

HIV In Primary Care



Specialist Services
Secure Services
Mental Health
Community Services
Children and Families

“Supporting early
testing, prevention and
management of HIV in
Primary Care”



HIV In Primary Care

SHIP Team

Aims of today's session

- Overview of HIV century.
- Identify methods of transmission for HIV.
- Risk assessments for HIV testing.
- Pre & post test discussions & testing in primary care.
- Prevention work in primary care.



Human Immunodeficiency Virus

We all have an HIV status


- ¶ Test HIV positive
- ¶ Test HIV negative
- ¶ Untested
- ¶ How open can you be about your HIV status
- ¶ HIV is an issue for us all !!

Potential Benefits of Early HIV Diagnosis

- ✿ May reduce risk of HIV acquisition by HIV negative individuals.
- ✿ Allows for early initiation of antiretroviral therapy:
 - Benefits HIV-infected individual.
 - May also reduce transmission to uninfected partners.

Adverse consequences of late HIV diagnosis


- ribbon Higher risk of serious, life-threatening opportunistic infections.
- ribbon Lower likelihood of CD4+ cell preservation, immune reconstitution to normal levels.
- ribbon Risk of potentially irreversible HIV-induced immunologic changes, end-organ damage.
- ribbon Lack of knowledge of sero- status associated with higher risk sexual activity and possible transmission.



Epidemiology of HIV Aetiology and disease progression

GLOBAL REPORT

Estimated adult and child deaths from AIDS | 2009




Total: 1.8 million [1.6 million – 2.1 million]

Number of new HIV diagnoses¹ by prevention group, UK: 2000-2009



Protecting people
Preventing harm
Preparing for threats




¹ Data are adjusted for missing route of infection

² Includes Mother to child transmission and blood product recipient




Estimated number of adults (15-59 years) living with HIV (both diagnosed and undiagnosed) in the UK: 2009






Annual New HIV diagnoses among men who have sex with men: UK, 1981-2010



Annual new HIV diagnoses acquired heterosexually: UK, 1981-2010




Protecting people
Preventing harm
Preparing for threats



Diagnosed HIV-infected individuals seen for care by ethnicity*, UK: 2000 and 2009, UK


White Black Caribbean Black African Asian / Oriental Other / mixed



* Excludes individuals with ethnicity not reported: 1,416 in 2000 and 934 in 2009

HIV Exposures in North West

Type of exposure	2010 (12/12)	2011 (6/12)
MSM	48%	54%
Heterosexual contact	37%	37%
IVDU	2.5%	0.6%
Vertical Transmission	0.3%	0.6%
Blood / tissue products	0.1%	0
Other	0.1%	0
Not reported	11.2%	7.3%



Who should be offered an HIV test ?


An HIV test should be considered in settings where the diagnosed HIV prevalence in local population (PCT/LA) exceeds 2 in 1000 population.

HIV prevalence data by PCT available at:

http://www.hpa.org.uk/Web/HPAwebFile/HPAweb_C/1228207185359

2010: A global view of HIV infection

33.3 million people [31.4–35.3 million] living with HIV, 2009



http://www.unaids.org/documents/20101123_2010_HIV_Prevalence_Map_em.pdf

Source: UNAIDS

No data < 0.1% 0.1% – < 0.5% 0.5% – < 1.0% 1.0% – < 5.0% 5.0% – < 15.0% 15.0% – 28.0%


HIV prevalence in Central and South America




HIV prevalence in sub-Saharan Africa



HIV prevalence in Asia



HIV prevalence in Eastern Europe and Central Asia



To calculate the adult HIV prevalence rate, we divided the estimated number of adults (15–49) living with HIV in 2009 by the 2009 population aged 15–49.

Depending on the reliability of the data available, there is more or less certainty surrounding any estimate of HIV prevalence. We use a range, called 'plausibility bounds' around the estimates. The wider the bound, the more uncertainty there is surrounding the country's estimate. The entire range of uncertainty is determined by the type of epidemic, and the quality, coverage and consistency of a country's surveillance system and its reporting system. If no survey or a population-based survey with HIV testing was conducted, a full description of the methods used to derive plausible bounds is provided in Section 3 (Technical notes, 2010, M-04-02).

The designation employed in the presentation of the material in this map, including tables and colouring of country areas, do not imply the recognition of the status of these areas by the part of UNAIDS or WHO concerning the legal status of any country, territory, city or area or of its administrative status, or the delimitation of its frontiers or boundaries.

The UNAIDS Report on the Global AIDS Epidemic 2010 revises the estimate of the number of people living with HIV in 2009 to 33.4 million (32.9 million–34.7 million), which is within the uncertainty bounds of the 2009 estimate. This revision is based on additional data becoming available for many countries, including data from population-based surveys such as a Malaria, Africa, and Malaria and HIV survey.


Additional updates to the 2009 HIV estimates included Mexico, Latin America. The UNAIDS Global Report 2010 includes Mexico in North America and categorizes the rest of Latin America as a single region, South America. This report presents revised estimates based on the new definition of these regions.


Source: UNAIDS Report on the Global AIDS Epidemic, 2010.

Estimated adult (15–49) HIV prevalence (%) for countries in 2009

Country/Region	Estimate	[low estimate – high estimate]
Sub-Saharan Africa		
Angola	2.2	[1.8 – 3.4]
Burkina Faso	1.2	[1.0 – 1.8]
Burundi	2.6	[1.0 – 4.2]
Cameroon	3.3	[4.9 – 5.8]
Central African Republic	4.7	[4.7 – 5.7]
Chad	3.4	[2.8 – 3.9]
Comoros	0.1	[-0.1 – 0.1]
Côte d'Ivoire	3.4	[3.1 – 3.9]
Democratic Republic of the Congo	2.4	[2.2 – 2.8]
Equatorial Guinea	9.0	[3.5 – 4.4]
Eswatini	0.8	[0.1 – 1.2]
Gabon	3.2	[1.5 – 4.9]
Ghana	1.8	[1.8 – 2.8]
Greece	0.1	[-0.1 – 0.1]
Kenya	2.5	[2.0 – 3.0]
Liberia	3.8	[3.1 – 4.5]
Madagascar	0.2	[-0.1 – 0.3]
Malawi	11.0	[10.0 – 12.1]
Mali	1.0	[0.5 – 1.5]
Mauritania	0.7	[0.4 – 0.9]
Morocco	1.5	[1.0 – 2.0]
Mozambique	11.5	[10.4 – 12.5]
Namibia	33.1	[11.3 – 34.8]
Niger	0.8	[0.5 – 1.2]
Nigeria	3.6	[2.6 – 4.6]
Rwanda	2.5	[1.5 – 3.5]
Saint Lucia	0.9	[0.2 – 1.6]
Senegal	1.8	[1.2 – 2.8]
Seychelles	0.9	[0.1 – 1.7]
Sierra Leone	1.8	[1.2 – 2.8]
South Africa	17.8	[17.2 – 18.8]
Swaziland	25.9	[24.9 – 27.1]
Togo	3.2	[2.0 – 4.4]
Uganda	6.5	[5.9 – 6.9]
Yemen	5.8	[5.2 – 6.8]
Zambia	13.5	[12.3 – 14.7]
Zimbabwe	16.3	[14.4 – 17.5]
East Asia		
China	0.1	[-0.1 – 0.1]
Democratic People's Republic of Korea	0.1	[-0.1 – 0.1]
Japan	0.3	[0.1 – 0.5]
South Korea	0.03	[-0.1 – 0.1]
Republic of Korea	0.1	[-0.1 – 0.1]
Timor-Leste	0.1	[-0.1 – 0.2]
Eastern Europe and Central Asia		
Bangladesh	-0.1	[-0.3 – -0.1]
Bosnia and Herzegovina	0.2	[0.0 – 0.4]
Bulgaria	0.3	[0.0 – 0.6]
China	0.2	[0.1 – 0.4]
Croatia	0.2	[0.1 – 0.4]
Georgia	-0.1	[-0.1 – -0.1]
India	0.2	[0.1 – 0.4]
Iran, Islamic Republic of	0.2	[0.1 – 0.4]
Kazakhstan	0.2	[0.1 – 0.4]
Kiribati	0.1	[0.1 – 0.2]
Kiribati	0.1	[0.1 – 0.2]
Kyrgyzstan	0.1	[0.1 – 0.2]
Latvia	0.1	[0.1 – 0.2]
Lebanon	0.1	[0.1 – 0.2]
Lithuania	0.2	[0.1 – 0.3]
Macedonia	0.2	[0.1 – 0.3]
Maldives	-0.1	[-0.1 – -0.1]
Mongolia	0.4	[0.3 – 0.5]
Nepal	0.4	[0.3 – 0.5]
Palau	0.1	[0.1 – 0.2]
Philippines	-0.1	[-0.1 – -0.1]
Singapore	0.1	[0.1 – 0.2]
Tajikistan	0.1	[0.1 – 0.2]
Turkmenistan	0.1	[0.1 – 0.2]
Ukraine	1.3	[1.0 – 1.6]
Uzbekistan	0.1	[0.1 – 0.2]
Eastern Europe and Central Asia		
Armenia	0.1	[-0.1 – 0.1]
Georgia	0.1	[-0.1 – 0.1]
Bolivia	0.3	[0.2 – 0.5]
Bulgaria	0.1	[-0.1 – 0.1]
Croatia	0.2	[0.1 – 0.3]
Georgia	0.1	[-0.1 – 0.1]
India	0.2	[0.1 – 0.4]
Iran, Islamic Republic of	0.2	[0.1 – 0.4]
Kazakhstan	0.1	[-0.1 – 0.1]
Kiribati	0.1	[-0.1 – 0.1]
Kiribati	0.1	[-0.1 – 0.1]
Kyrgyzstan	0.1	[-0.1 – 0.1]
Latvia	0.2	[0.1 – 0.4]
Lithuania	0.1	[-0.1 – 0.1]
Macedonia	0.2	[0.1 – 0.3]
Maldives	0.2	[0.1 – 0.3]
Mongolia	0.2	[0.1 – 0.3]
Nepal	0.1	[-0.1 – 0.1]
Palau	0.1	[-0.1 – 0.1]
Philippines	0.1	[-0.1 – 0.1]
Singapore	0.1	[-0.1 – 0.1]
Tajikistan	0.1	[-0.1 – 0.1]
Turkmenistan	0.1	[-0.1 – 0.1]
Ukraine	1.3	[1.0 – 1.6]
Uzbekistan	0.1	[-0.1 – 0.1]
Eastern Europe and Central Asia		
Austria	0.2	[0.2 – 0.4]
Bosnia and Herzegovina	0.2	[0.1 – 0.3]
Bulgaria	0.1	[-0.1 – 0.1]
Croatia	0.2	[0.1 – 0.3]
Georgia	-0.1	[-0.1 – -0.1]
India	0.2	[0.1 – 0.4]
Iran, Islamic Republic of	0.2	[0.1 – 0.4]
Kazakhstan	0.1	[-0.1 – 0.1]
Kiribati	0.1	[-0.1 – 0.1]
Kiribati	0.1	[-0.1 – 0.1]
Kyrgyzstan	0.1	[-0.1 – 0.1]
Latvia	0.2	[0.1 – 0.3]
Lithuania	0.1	[-0.1 – 0.1]
Macedonia	0.2	[0.1 – 0.3]
Maldives	0.2	[0.1 – 0.3]
Mongolia	0.2	[0.1 – 0.3]
Nepal	0.1	[-0.1 – 0.1]
Palau	0.1	[-0.1 – 0.1]
Philippines	0.1	[-0.1 – 0.1]
Singapore	0.1	[-0.1 – 0.1]
Tajikistan	0.1	[-0.1 – 0.1]
Turkmenistan	0.1	[-0.1 – 0.1]
Ukraine	1.3	[1.0 – 1.6]
Uzbekistan	0.1	[-0.1 – 0.1]
Eastern Europe and Central Asia		
Austria	0.2	[0.2 – 0.4]
Bosnia and Herzegovina	0.2	[0.1 – 0.3]
Bulgaria	0.1	[-0.1 – 0.1]
Croatia	0.2	[0.1 – 0.3]
Georgia	-0.1	[-0.1 – -0.1]
India	0.2	[0.1 – 0.4]
Iran, Islamic Republic of	0.2	[0.1 – 0.4]
Kazakhstan	0.1	[-0.1 – 0.1]
Kiribati	0.1	[-0.1 – 0.1]
Kiribati	0.1	[-0.1 – 0.1]
Kyrgyzstan	0.1	[-0.1 – 0.1]
Latvia	0.2	[0.1 – 0.3]
Lithuania	0.1	[-0.1 – 0.1]
Macedonia	0.2	[0.1 – 0.3]
Maldives	0.2	[0.1 – 0.3]
Mongolia	0.2	[0.1 – 0.3]
Nepal	0.1	[-0.1 – 0.1]
Palau	0.1	[-0.1 – 0.1]
Philippines	0.1	[-0.1 – 0.1]
Singapore	0.1	[-0.1 – 0.1]
Tajikistan	0.1	[-0.1 – 0.1]
Turkmenistan	0.1	[-0.1 – 0.1]
Ukraine	1.3	[1.0 – 1.6]
Uzbekistan	0.1	[-0.1 – 0.1]
Eastern Europe and Central Asia		
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 – 0.3]
Guatemala	0.2	[0.1 – 0.3]
Honduras	0.2	[0.1 – 0.3]
Uruguay	0.2	[0.1 – 0.3]
Venezuela, Bolivarian Republic of	0.2	[0.1 – 0.3]
Argentina	0.5	[0.2 – 0.8]
Bolivia	0.2	[0.1 – 0.3]
Bulgaria	0.2	[0.1 – 0.3]
Chile	0.4	[0.2 – 0.5]
Colombia	0.4	[0.2 – 0.5]
Costa Rica	0.2	[0.1 – 0.3]
Ecuador	0.4	[0.2 – 0.5]
Georgia	0.2	[0.1 –

HIV progression







Risk Factors for HIV

Individuals diagnosed with HIV risk 2010



37%



2.5%




48%

Wellbeing



0.3%



HIV testing in Primary Care

Who should be offered HIV testing ?



- ❧ All patients with symptoms indicative of HIV.
- ❧ All patients diagnosed with STI.
- ❧ All sexual partners of men and women known to be HIV positive.
- ❧ All men who have disclosed sexual contact with other men. (MSM)
- ❧ All female contacts of MSM.
- ❧ All patients reporting history of Injecting drug use.
- ❧ All patients known to be from country of high prevalence.
- ❧ All patients reporting sexual contact abroad or in UK with individuals from countries of high prevalence.

Recommended universal HIV testing for ...

- ❧ GUM or Sexual Health services.
- ❧ Antenatal services.
- ❧ Termination of pregnancy services.
- ❧ Drug dependency programmes.
- ❧ Healthcare services for those diagnosed with:
 - TB
 - Hepatitis B & C
 - Lymphoma

Existing Department of Health Guidance advocates testing for ...

- Blood donors.
- Dialysis patients.
- Organ transplant donors and recipients.

Confidentiality is central to trust between doctors and patients.

Without assurances about confidentiality, patients may be reluctant to seek medical attention or to give doctors the information they need in order to provide good care.



Go to
www.gmc-uk.org/confidentiality
for more information
and advice.

Treatment Costs

- ¶ £18000 annually for HIV positive (without symptoms) patient care.
- ¶ £21500 annually for HIV positive (with symptoms) patient care.
- ¶ £41000 annually for HIV positive (AIDS stage) patient care.
- ¶ *Annual cost of patients accessing healthcare in 2006 was £483 million.*
- ¶ *Add Social & community care costs the bill escalates to some £683 million a year!*


What's the future cost?

By 2013 it is estimated that there will be
78370 people accessing NHS HIV care costing
£720-758 million

With social care the bill is estimated to be
£1065 million

Pre test discussion

????



Points to consider before blood borne virus testing



- ❑ Reason for test.
- ❑ Assessment of risk.
- ❑ Understanding of blood borne virus issues.
- ❑ Informed consent & confidentiality.
- ❑ Coping with the wait for results.
- ❑ Implications of a positive test, who to tell.
- ❑ How to obtain results.
- ❑ Window period and follow up.
- ❑ Leaflet.

Blood Testing



- ❖ Clotted blood specimen for:
HIV antibody
p24 antigen
- ❖ Serology may take **3 months** to become positive.
- ❖ Repeat test should be offered if **3 month** window period is not covered.

Giving Results

Negative results

- ❑ Health Promotion aimed at safer sex or changing behaviour.
- ❑ Possible STI screen.
- ❑ Possible need for re-testing (window period).

Positive Results

- ❑ Time to prepare yourself.
- ❑ Support from specialist GUM professionals.
- ❑ Review your initial consultation.
- ❑ Give the result without delay.
- ❑ Informed consent to refer to GUM.
- ❑ Risk reduction and protecting partners.

Prevention work in Primary Care

- ribbon THINK! 'high risk' groups.
- ribbon Don't forget 'window period' testing.
- ribbon Offer free condoms within the surgery.
- ribbon Remember oral sex risk.
- ribbon Remember co infection risk groups.



Prevention work in Primary Care

- ribbon icon Clinical indicator conditions, i.e. respiratory, gastroenterology & dermatology.
- ribbon icon Reassure about confidentiality within the practice.
- ribbon icon Regular routine testing.



Thinking high risk groups...



Young People



Injecting drug users



MSM



Black Africans

Case Studies

HIV



Case Study John

- John is a 35 year old teacher.
- Married to Jane for 8 years and has two children.
- Attends today complaining of non itchy rash and persistent sore throat / flu like symptoms for one week.
- Medical history unremarkable .

Case study John - Initial examination

- ❑ Signs of pharyngitis
- ❑ Four oral mouth ulcers
- ❑ Cervical Lymphadenopathy
- ❑ Rash to the trunk



- ❑ What is your differential diagnosis?
- ❑ What investigations would you take at this time?



Case study John

Follow up

- John returns to your practice 3 days later feeling worse, sore throat, fever and rash persist.
- Throat swab and full blood count normal and serology for glandular fever negative.

How would you open discussion around Sexual Health?

It's important to feel comfortable and work within your own style of communication.

Role play the discussion

Before moving onto next sheet

Case study John

Sexual history

- >Last had sex with his wife 8 days ago does not use condoms.
- John is bisexual.
- Three semi regular male partners.
- Uses condoms for anal sex but not oral sex.
- Had receptive anal sex three weeks ago but the condom came off.

Case Study John Further management

Investigations

- ❑ HIV test.
- ❑ Serology for syphilis.
- ❑ Hepatitis A IgG.
- ❑ Hepatitis B Screen

Points to consider

- ❑ Window period 3 months.
- ❑ Health promotion safe sex using condoms for oral sex.
- ❑ Hepatitis B immunisation.

Case study John results

- ❖ HIV antibody – not detected.
- ❖ HIV p24 antigen test – detected (provisional).
- ❖ Syphilis – not detected.
- ❖ Hepatitis A IgG – not detected.
- ❖ Hepatitis B antibody/ antigen – No evidence of current or past infection.
- ❖ Diagnosis – Primary HIV seroconversion illness (provisional result).


Case study John

What further issues are there to consider?

- ❗ John's wife has been placed at risk and is unaware of his bisexuality.
- ❗ She is also one of your patients - you have a duty of care to her.
- ❗ Partner notification of other partners.

How do you resolve this conflict of care?

Mouth lesions associated with HIV



Oral Candidiasis



Angular cheilitis



Oral hairy leukoplakia



Kaposi's sarcoma of the mouth

Case study Alan

- Alan is a 45 year old clerk who lives in Manchester.
- Last attended 4 months ago with a history of eczema which cleared with hydrocortisone cream but has now returned.
- Noticed a mole on his hand 4 weeks ago has become darker and grown slightly, non painful or itchy.
- Generally unwell complaining of fatigue, intermittent diarrhoea and dry scaly skin.

Case study Alan - examination

- ❑ Scaly rash.
- ❑ Cervical Lymphadenopathy.
- ❑ White lesions on the side of the tongue.

- ❑ **What is your differential diagnosis?**

- ❑ **What investigations would you take at this time?**



How would you open the discussion around a weakened immune system?

It's important to feel comfortable and do this in your own style of communication.

Role play the discussion

Before moving onto next sheet

Case study Alan further history including Sexual History

- >You ask Alan about travel. He holidays in the UK, has limited sun exposure and uses high factor sun screen. He has never used a sun bed.
- In a long term relationship with Mark for 3 years.
- Mark lives 50 miles away and Alan spends time with him most weekends.
- Alan has been sexually active since he was 19 and has only had male partners.
- He practises oral and receptive anal sex and no longer uses condoms with Mark.
- Last sexual intercourse 7 days ago.

Case Study Alan

Investigations

- ❑ HIV test.
- ❑ Serology for syphilis.
- ❑ Hepatitis A IgG.
- ❑ Hepatitis B screen.

Points to consider

- ❑ Window period 3 months.
- ❑ Health promotion safe sex using condoms for oral sex.
- ❑ Hepatitis B immunisation.

Case Study Alan results

- HIV antibody & P24 antigen – detected (provisional).
- Syphilis – detected.
- Hepatitis A IgG – not detected.
- Hepatitis B antibody/ antigen – no evidence of current or past infection.
- Diagnosis – HIV positive (provisional result).

Case study Alan further management and issues

- Refer to HIV specialist.
- Partner notification Mark has been placed at risk.
- Ongoing support may be required around diagnosis, disclosure to others, confidentiality ...
- May need referral to supportive agencies.

Kaposi's sarcoma


- Kaposi's sarcoma is a strong indicator of immunosuppression.
- It is the most significant lymphoma associated with HIV.
- AIDS defining condition – multiple sites such as arm, trunk, palate, face and feet. Internal lesions in the lungs or GI tract can cause serious complications leading to death.



Constitutional symptoms associated with HIV



**Facial Molluscum
Contagiosum**



**Atypical
Seborrhoeic
dermatitis**

Case study - Dominique

- ❶ 22 year old female visiting from Tanzania.
- ❶ Staying with relatives and has registered as a temporary patient with you.
- ❶ Attends today with her Aunt who is concerned at Dominique's weight loss.
- ❶ Dominique complains of fatigue and night sweats which have become worse over the last few weeks.

Case study Dominique - examination

- ❑ Signs of severe weight loss – 44kg.
- ❑ Oral Candidiasis.
- ❑ Temperature 38 degrees c.
- ❑ Cervical Lymphadenopathy palpable non tender rubbery axillary and inguinal nodes.
- ❑ Palpable non tender liver.
- ❑ Chest is clear.
- ❑ Dry skin.

- ❑ What is your differential diagnosis?
- ❑ What investigations /actions would you consider at this time?



**How would you open the discussion around weakened
immune system and
HIV high prevalence issues ?**

**It's important to feel comfortable and do this in
your own style of communication.**

Discuss

Before moving onto next sheet

Case study Dominique –further history

- ❶ Born /resident in a country with high prevalence of HIV.
- ❶ Dominique has been in a regular sexual relationship in Tanzania with Samuel. Samuel is well.
- ❶ Dominique has had two other sexual partners, both in Tanzania, in the past.
- ❶ She has never used condoms.
- ❶ She has never had a HIV test.

How do you proceed?

Case Study Dominique Hospital Results

- HIV antibody & p24 antigen detected
- CD4 count 86 cells/mm³
- Viral load 200,000 copies/ml
- Indicates advanced immunosuppression with a high level of circulating HIV.
- HIV infection with constitutional symptoms.

Blood counts in HIV infection

CD4 cells/mm³ count normal range

- 400-1200 normal range men
- 500-1600 normal range women
- 200 – 500 indicates some damage to immune system
- 200 & below risk of opportunistic infections

We also look at

Viral load 1.0 logs = 10 copies

1.5 logs = 32 copies

5.5 logs = 316,228 copies

Case Study Dominique further management and considerations

- Visitor to UK – eligible to limited care.
- Emergency hospital care but not inpatient care.
- Certain communicable diseases i.e. TB are eligible to NHS treatment.
- Treatment for HIV AIDS and antiretroviral medication as a life saving treatment will not be denied, but long term HAART maybe an issue.

	AIDS defining conditions	Other conditions where HIV testing should be offered
Respiratory	Tuberculosis Pneumocystis	Bacterial pneumonia Aspergillosis
Neurology	Cerebral toxoplasmosis Primary cerebral lymphoma Cryptococcal meningitis Progressive multifocal leucoencephalopathy	Aspectic meningitis/encephalitis Cerebral abscess Space occupying lesion of unknown cause Gullain Barre Syndrome Transverse myelitis Peripheral neuropathy Dementia Lecoencephalopathy
Dermatology	Kaposi's sarcoma	Severe or recalcitrant seborrhoeic dermatitis Severe or recalcitrant psoriasis Multidermatomal or recurrent herpes zoster
Gastroenterology	Persistent Cryptosporidiosis	Oral candidiasis Oral hairy leukoplakia Chronic diarrhoea of unknown cause Salmonella, shigella or campylobacter Hepatitis B infection Hepatitis C infection



Oncology	Non-Hodgkin's lymphoma	Anal cancer or anal intraepithelial dysplasia Lung cancer Seminoma Head & neck cancer Hodgkin's lymphoma Castleman's disease
Gynaecology	Cervical cancer	Vaginal intraepithelial neoplasia Cervical intraepithelial neoplasia Grade 2 and above
Haematology		Any unexplained blood dyscrasia including: Thrombocytopenia Neutropenia Lymphopenia
Ophthalmology	Cytomegalovirus retinitis	Infective retinal disease including herpes viruses and toxoplasma Any unexplained retinopathy
ENT		Lymphadenopathy of unknown cause Chronic parotitis Lymphoepithelial parotid cysts
Other  Supporting Health and Wellbeing		Mononucleosis like syndrome (primary HIV infection) Pyrexia unknown origin Any lymphadenopathy of unknown cause Any sexually transmitted infection

What happens following a positive HIV diagnosis ?

Did You Just Test-
HIV Positive?



Monitoring HIV


Patients wishes

Clinical signs

Treatment

CD4 count



Viral load



Supporting Health and Wellbeing

CONFIDENTIALITY

?



Adjusting to living with HIV

Disclosure of status

Partner notification

**Avoiding or preventing
other infections**

**Sexual health &
relationships**

Pregnancy & family life

Risk reduction

Behavioural changes

**Emotional & mental
health**

Drugs, alcohol, smoking

Food, drink, nutrition

Medication

Illness

Travel/holidays/immigration

Employment/careers

Finance / Insurance

Future

Shared Care with HIV Consultant

- GP for regular health care needs
- Investigations and results
- Hospital outpatients / inpatients care
- Antenatal care
- HIV Consultant – specialist HIV care

All reduces risk of drug interactions

<http://www.hiv-druginteractions.org/>

Conclusion



This is a **REAL** opportunity for change

- ribbon icon Traditionally HIV testing was seen as the remit of GUM.
- ribbon icon It's time the change was made to widen the increase in opportunistic screening for HIV.
- ribbon icon Late diagnosis contributes to morbidity and mortality.



References

- British HIV Association (2009) *Don't forget the Children: Guidance for HIV testing of children with HIV-positive parents*. London: Mediscript Ltd
- Gilead (2010) *Early Testing saves Lives: Halve it.*
- Health protection Agency (2007): Testing times HIV and other Sexually Transmitted infection in the UK 2007
- Health Protection Agency (2010) *Time to test for HIV: Expanded healthcare and community HIV testing in England*. HPA
- National Institute of Clinical Excellence (2011) *Increasing the Uptake of HIV Testing Among Black Africans in England*, NICE.
- National Institute of Clinical Excellence (2011) *Increasing the Uptake of HIV Testing Among Men Who Have Sex with Men in England*, NICE.
- Madge, S., Mathews, P., Singh, S., Theobald, N (2005) : HIV in Primary Care : MedFASH
- UK Collaborative Group for HIV and STI Surveillance. (2006) *A Complex Picture. HIV and other Sexually Transmitted Infections in the United Kingdom*. London: Health Protection Agency, Centre for Infections. November 2006

References

- <http://www.nwpho.org.uk/hiv/>
- <http://www.medfash.org.uk/>
- <http://www.cph.org.uk/sexualhealth.asp>
http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1221482344001
- <http://www.bhiva.org/ClinicalGuidelines.aspx>
- www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf
- <http://www.bashh.org/guidelines>



Thank You
for taking part.



Supporting Health and Wellbeing